Pesquisar
CRISPR Therapeutics AG
CRSPAdicionar à lista de desejos
59.130USD
+2.570+4.54%
Horário de mercado 09/21, 14:19（ET）
5.72BValor de mercado
PerdaP/L TTM
Mais detalhes de CRISPR Therapeutics AG Empresa
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
CRISPR Therapeutics AG Perfil
Código da empresaCRSP
Nome da EmpresaCRISPR Therapeutics AG
Data de listagemOct 19, 2016
CEOKulkarni (Samarth)
Número de funcionários393
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 19
EndereçoBaarerstrasse 14
CidadeZUG
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSwitzerland
Código postalCH-6300
Telefone41415613279
Sitehttps://crisprtx.com/
Código da empresaCRSP
Data de listagemOct 19, 2016
CEOKulkarni (Samarth)
Executivos da empresa CRISPR Therapeutics AG
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
255.50K
+11.50%
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
255.50K
+11.50%
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
255.50K
+11.50%
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
19.36K
+32.10%
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
19.36K
+32.10%
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
19.36K
+32.10%
Mr. Raju Prasad, Ph.D.
Mr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
14.81K
-5.06%
Mr. Raju Prasad, Ph.D.
Mr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
14.81K
-5.06%
Mr. Raju Prasad, Ph.D.
Mr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
14.81K
-5.06%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
255.50K
+11.50%
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
255.50K
+11.50%
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
255.50K
+11.50%
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
19.36K
+32.10%
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
19.36K
+32.10%
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
19.36K
+32.10%
Perguntas frequentes
Quem são os cinco principais acionistas de CRISPR Therapeutics AG?
Os cinco principais acionistas de CRISPR Therapeutics AG são: Dr. Samarth Kulkarni, Ph.D.
Quantas instituições possuem ações da CRISPR Therapeutics AG (CRSP)?
Em 2026Q1, 1020 instituições possuíam ações da CRISPR Therapeutics AG, com valor de mercado aproximado de 75.38M, representando 78.16% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -5899589.00.